$QDEL

QuidelOrtho Corp (QDEL): Submission of Matters to a Vote of Security Holders

QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K QuidelOrtho Corp false 0001906324 0001906324 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event rep

Original reporting
Published Jun 16, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$QDEL
Neutral
high confidence
Mentioned
$QDEL
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QDELNeutralLow
01

Why it matters

The disclosure confirms governance outcomes (board nominees elected, advisory executive compensation approved, KPMG ratified) but does not introduce new financial guidance, litigation, product, or regulatory developments.

02

Market read

Primarily informational for governance records; not a fundamental catalyst for trading.

03

What to watch

Traders may still monitor whether any director nominees or auditor ratification outcomes differ from expectations, but this text alone does not provide such context.

Relevance 6/10Novelty 2/10Timing: Filed June 16, 2026 (after the annual meeting)

Background

The filing is an SEC Form 8-K for Item 5.07, reporting final results of proposals voted on at QuidelOrtho’s 2026 annual meeting.

Company-level read

Ticker impact

$QDELNeutralHigh confidence
Context

QuidelOrtho reported final voting results from its June 16, 2026 annual meeting, including director elections and advisory say-on-pay.

Expected impact

Likely minimal near-term impact; any reaction would be limited to governance/technical positioning rather than fundamentals.

Evidence & confidence

The 8-K item is a standard disclosure of vote tallies (directors, say-on-pay, auditor ratification) without changes to guidance, strategy, or material events.

Market effects

None; this is company-specific governance reporting.

None indicated; US-listed issuer filing only.

None; no cross-border transaction or regulatory action mentioned.

Counterpoint

If the vote results were unusually close or contentious, it could hint at shareholder dissatisfaction, but the filing provides no narrative or threshold outcomes beyond tallies.

Key entities

  • QuidelOrtho Corporation

    US-listed issuer filing the 8-K with final shareholder vote results.

  • KPMG LLP

    Independent registered public accounting firm ratified for the 2026 fiscal year.

Related articles

$UPCMed

Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

$QDELMedAI 8/10

QuidelOrtho (NASDAQ:QDEL) Stock Price Up 9.4% – Here’s What Happened

QuidelOrtho (NASDAQ:QDEL) shares rose 9.4% to about $13.49 midday Thursday, after closing at $12.33. The stock traded as high as $13.55 on lighter volume (637,880 shares vs. 1.85M average). The move followed recent analyst target cuts and mixed ratings. In its May 5 earnings, the company reported Q EPS of -$0.04 vs. $0.37 expected and revenue of $619.8M vs. $665.2M.

$COPMed

ConocoPhillips completes $1.7 billion asset sale, hits divestiture target early

ConocoPhillips said it completed a $1.7 billion sale of noncore Lower 48 assets in July, helping it reach its $5 billion divestiture target ahead of schedule. Reuters reports the company disclosed the sale with its Q2 results, noting $200 million in noncore sale proceeds in the quarter and $3 billion in capex/investments. It also reported better-than-expected profit and leadership changes.

$FRTMedAI 8/10

Federal Realty Announces Proposed Private Placement of $400 Million of Exchangeable Senior Notes

Federal Realty Investment Trust (NYSE: FRT) said its operating partnership launched a private placement of $400 million exchangeable senior notes due 2031, with an option for initial purchasers to buy up to an additional $60 million. Notes accrue semiannual interest and may be exchanged for cash and/or FRT common shares. Net proceeds will fund capped call costs, debt repayment, and general corporate purposes.